Cube Blog around you eyes

Aragonesa Foundation works with the Federation to support MPS patients.

Zaragoza, May 17 .- The Aragonesa Science Foundation for the Study of Rare Diseases, Feeteg, and the Spanish Federation representing MPS patients with mucopolysaccharidosis and related syndromes have signed a collaboration agreement to support patients who suffer this type of pathologies.

Pilar Giraldo, Miguel Servet Hospital hematologist and director of the Feeteg stressed the importance of the public authorities' support, sto credits, when diagnosing and treating these patients, who are facing "numerous obstacles for the huge expenditure involved its diagnostic and genetic tests and subsequently access their medications in case there. "

The agreement is therefore a first step to support this type of associations of patients and "to advance together hand in hand" feature Giraldo on the occasion, buy darkfall gold, of the celebration in Zaragoza World Day of MPS diseases and syndromes related reported the Federation MPS sources.

Giraldo has underlined its commitment to the Associations of patients and especially with the MPS, which brings together patients affected by lysosomal and related syndromes such as Fabry disease, "which affected are suffering from shortages of medicine a year, Gaia Gold, ago by multiple contamination Fabrazyme Genzyme lab, "as happens to those affected by Gaucher's disease with the drug Cerezyme.

For its part, Jordi Cruz, president of the Federation MPS Spain, I am confident that this alliance "will help us gain access as soon as possible gene therapy (transplantation of genes) that is already so advanced by some researchers to treat Catalan one of our lysosomal pathologies. "

In Spain, there are 2,000 people affected by Fabry disease and Gaucher's disease who claim that this situation is regularized.

Gene therapy aims to cure inherited or acquired diseases (which in many cases are caused by dctive genes) by inserting functional copies of dctive or missing genes in the genome of an individual. Allows the exact location of these candidate genes to replace dctive by other incorrect.

The technique is still in development, which is why their application is carried out mainly within controlled clinical trials, report the sources cited.